Teva- Pharmaceutical Industries Overview
Teva- Pharmaceutical Industries (TEVA) has a P/E ratio of 62.59, above the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow62.59
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Teva- Pharmaceutical Industries's p/e ratio stands at 62.59. That is above the Healthcare sector average of 25.3. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Teva- Pharmaceutical Industries sits higher the Healthcare benchmark (25.3) with a P/E ratio of 62.59. That is roughly 147.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether 62.59 is attractive depends on Teva- Pharmaceutical Industries's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Teva- Pharmaceutical Industries's P/E ratio evolved across reporting periods, while the comparison chart places TEVA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Teva- Pharmaceutical Industries's reading of 62.59 (sector avg 25.3) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
